Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes
Colorectal Cancer Screening is now translated into multiple languages to help people worldwide understand why, when and how to screen for colorectal cancer
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
Pharma giant targets new standards of care
The long-term exposure to fine particulate matter (PM2.5) increases overall cancer risk by 11%
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Subscribe To Our Newsletter & Stay Updated
